Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on March 9, 2006

Stroke. 2006
Published online before print March 9, 2006, doi: 10.1161/01.STR.0000209239.71702.ce
A more recent version of this article appeared on April 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/4/1075    most recent
01.STR.0000209239.71702.cev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hylek, E. M.
Right arrow Articles by Regan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hylek, E. M.
Right arrow Articles by Regan, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Atrial Fibrillation
*Blood Thinners
Hazardous Substances DB
*WARFARIN
Related Collections
Right arrow Coumarins
Right arrow Thrombosis risk factors
Right arrow Anticoagulants

Submitted on November 11, 2005
Revised on January 20, 2006
Accepted on January 23, 2006

Translating the Results of Randomized Trials into Clinical Practice. The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation

Elaine M. Hylek MD, MPH*; James D’Antonio MD; Carmella Evans-Molina MD; Carol Shea RN; Lori E. Henault MPH; and Susan Regan PhD

From the Department of Medicine (E.M.H., L.E.H.), Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Mass; the Department of Medicine (J.D.), Cardiology Division, University of Pittsburgh, Pa; the Department of Medicine (C.E.-M.), University of Virginia, Charlottesville, Va; and the Department of Medicine (C.S., S.R.), Massachusetts General Hospital, Boston, Mass.

* To whom correspondence should be addressed. E-mail: ehylek{at}bu.edu.

Background and Purpose--Numerous studies have documented under use of warfarin particularly among elderly patients. A better understanding of the discrepancy between trials and clinical practice will help inform stroke prevention strategies in this vulnerable age group. The study objective was to prospectively assess the use of antithrombotic therapy among a contemporary cohort of patients with atrial fibrillation at the time of hospital discharge. In addition to baseline characteristics, we sought to define the physician-cited reason for not prescribing warfarin for each patient.

Methods--Patients with atrial fibrillation were prospectively identified and followed to hospital discharge. Enrolled patients were ≥65 years of age, not taking warfarin on admission, and had their longitudinal care provided at our institution. Predictors of warfarin use were determined and physician-cited contraindications were compared across age groups.

Results--Fifty-one percent (n=206) of patients were discharged on warfarin: 75% of those 65 to 69 years of age, 59% 70 to 79, 45% 80 to 89, and 24% age ≥90 years. Of the remaining 199 patients, 83% had ≥2 major risk factors for stroke, and 98% were felt to have contraindications including nearly 25% who were unable to tolerate warfarin in the past. Among patients age ≥80, falling was the most often physician-cited reason for not prescribing warfarin (41%) followed by hemorrhage (28%).

Conclusion--Our findings suggest that many elderly patients at high risk for stroke may not be optimal candidates for anticoagulant therapy. There is a pressing need for alternative stroke prevention strategies for this expanding patient population.
Key words: atrial fibrillation • geriatrics • warfarin




This article has been cited by other articles:


Home page
 NEJMHome page
The ACTIVE Investigators
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
N. Engl. J. Med., May 14, 2009; 360(20): 2066 - 2078.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C. van Walraven, R. G. Hart, S. Connolly, P. C. Austin, J. Mant, F.D. R. Hobbs, P. J. Koudstaal, P. Petersen, F. Perez-Gomez, J. A. Knottnerus, et al.
Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators
Stroke, April 1, 2009; 40(4): 1410 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. Beyer, R. Lee, and B.-K. Lam
Point: Minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation: early multicenter results.
J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 521 - 526.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. J. Gladstone, E. Bui, J. Fang, A. Laupacis, M. P. Lindsay, J. V. Tu, F. L. Silver, and M. K. Kapral
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke, January 1, 2009; 40(1): 235 - 240.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning
Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 546S - 592S.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf
Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation"
Circulation, February 5, 2008; 117(5): e150 - e150.
[Full Text] [PDF]

Home page
 EuropaceHome page
J. S. Taggar and G. Y.H. Lip
Anticoagulation for elderly patients with atrial fibrillation: not to be neglected
Europace, January 1, 2008; 10(1): 1 - 2.
[Full Text] [PDF]

Home page
 StrokeHome page
G. A. Ford, A. M. Choy, P. Deedwania, D. G. Karalis, C.-J. Lindholm, W. Pluta, L. Frison, S. B. Olsson, and on behalf of the SPORTIF III, V Investigators
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials
Stroke, November 1, 2007; 38(11): 2965 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
Circulation, July 24, 2007; 116(4): 449 - 455.
[Full Text] [PDF]

Home page
 CirculationHome page
E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Circulation, May 29, 2007; 115(21): 2689 - 2696.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
L. Testa, G. Trotta, A. Abbate, P. Agostoni, and G. G.L. Biondi-Zoccai
The Hurdles of Warfarin and the Hurdles of Clinical Practice
Stroke, December 1, 2006; 37(12): 2867 - 2867.
[Full Text] [PDF]

Home page
 StrokeHome page
A. Ono, I. Kawamura, and T. Fujita
Eligibility for Anticoagulation in Elderly Patients With Atrial Fibrillation
Stroke, September 1, 2006; 37(9): 2205 - 2205.
[Full Text] [PDF]

Home page
 StrokeHome page
C. Stollberger, J. Finsterer, and B. Schneider
Safety of Oral Anticoagulation in Elderly Atrial Fibrillation Patients to Prevent Strokes
Stroke, August 1, 2006; 37(8): 1960 - 1961.
[Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Elders with AFib Who Are Discharged Without Warfarin
Journal Watch Cardiology, May 4, 2006; 2006(504): 3 - 3.
[Full Text]


Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.